Health Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148… James Pereira Aug 17, 2022 CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage… Read More...
Health Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update James Pereira May 14, 2022 Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022… Read More...
Health Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference James Pereira Feb 21, 2022 CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage… Read More...
Health Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous… James Pereira Oct 22, 2021 CARLSBAD, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company… Read More...
Health Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China James Pereira May 9, 2021 CARLSBAD, Calif. and SHANGHAI, China, May 07, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), and… Read More...